Skip to main content
NVDA-0.19%AAPL+1.11%GOOGL-2.28%MSFT+0.03%AMZN-0.01%TSM-0.83%SPCX-3.86%AVGO-1.13%META+0.84%TSLA-0.42%SKHY+7.05%MU-1.35%BRK-B+0.18%LLY+0.02%JPM+0.34%AMD+3.04%WMT-0.21%V-0.34%XOM+2.24%ASMLa-1.54%JNJ-0.76%INTC+1.69%MA-0.59%0700.HK-1.94%ORCL-0.50%1398.HK+0.79%BAC+0.45%ABBV+0.88%CSCO+0.24%CVX+1.91%COST-0.83%LRCX-1.43%KO-0.92%CAT-0.84%AMAT-0.83%AP2d-0.65%0005.HK-0.78%HSBA.L-1.45%UNH-1.94%DELL+0.29%MS-0.42%PG-2.02%GE-2.83%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX-0.96%HD-1.04%GS-0.75%0939.HK+1.66%NZDJPY-2.22%CHFJPY-1.73%USDJPY-1.64%AUDJPY-1.55%EURJPY-1.46%CADJPY-1.44%GBPJPY-1.39%GBPNZD+0.83%NZDCAD-0.80%EURNZD+0.79%AUDNZD+0.70%NZDUSD-0.60%NZDCHF-0.52%GBPTRY+0.41%GBPCHF+0.33%GBPHKD+0.32%GBPMXN-0.28%CADCHF+0.28%EURCHF+0.27%GBPUSD+0.25%GBPZAR+0.22%EURZAR+0.22%EURNOK+0.21%USDZAR+0.21%USDNOK+0.20%NZDSGD+0.19%USDCAD-0.19%AUDCHF+0.19%EURUSD+0.18%NZDMXN+0.17%USDILS+0.16%CHFNOK+0.16%AUDCAD-0.14%GBPAUD+0.14%AUDDKK-0.12%USDTHB+0.12%NOKJPY-0.11%USDTRY+0.11%USDCHF+0.10%EURCZK-0.09%EURAUD+0.09%AUDNOK+0.09%AUDUSD+0.09%EURSEK+0.08%GBPSGD+0.07%EURSGD+0.07%EURPLN+0.07%USDSEK+0.07%USDSGD+0.06%USDPLN+0.06%USDMXN+0.06%AUDSGD-0.05%EURGBP-0.05%USDCOP-0.04%PLNJPY+0.03%USDCNH-0.03%SGDJPY+0.03%GBPCAD+0.03%CHFSEK+0.02%EURCAD-0.02%CHFSGD+0.02%USDHKD+0.01%USDDKK-0.01%EURDKK0.00%EURCNH0.00%EURHKD0.00%COFFEE-2.46%SUGAR+1.85%XPTUSD-1.72%COTTON+1.40%COCOA-1.30%GAGUSD-1.06%XAGUSD-1.04%HG1-0.97%USOIL+0.67%S1+0.53%C1+0.47%UKOIL+0.47%BTCUSD-0.43%ETHUSD0.00%USDTUSD-0.03%XRPUSD-1.28%SOLUSD-0.49%TRXUSDT+0.42%ZECUSDT-1.76%DOGEUSD-1.44%XMRUSDT-0.83%LINKUSD-0.08%XLMUSD-1.08%BCHUSDT-1.93%LTCUSD-1.59%UNIUSD-2.13%TONUSD+24.88%HBARUSDT-1.31%SUIUSD-1.38%TAOUSDT-1.11%AAVEUSD-1.67%DOTUSDT-2.18%ICPUSDT-1.08%ONDOUSDT-2.09%WLDUSDT-1.95%ATOMUSDT-2.11%ARBUSDT-0.27%JUPUSDT-2.96%INJUSDT-2.70%STXUSDT-2.70%FETUSDT-2.39%TIAUSDT-0.87%SEIUSDT-3.91%PYTHUSDT-1.24%IMXUSDT-2.27%WIFUSDT-2.93%GRTUSDT-2.33%OPUSDT-1.99%POLUSDT-3.22%IOTAUSDT-2.53%AXSUSDT-2.04%FARTCOINUSDT-1.57%EOSUSDT+0.06%DYDXUSDT-0.80%ORDIUSDT+0.59%GALAUSDT-3.09%NOTUSDT-0.68%RONINUSDT-0.71%NVDA-0.19%AAPL+1.11%GOOGL-2.28%MSFT+0.03%AMZN-0.01%TSM-0.83%SPCX-3.86%AVGO-1.13%META+0.84%TSLA-0.42%SKHY+7.05%MU-1.35%BRK-B+0.18%LLY+0.02%JPM+0.34%AMD+3.04%WMT-0.21%V-0.34%XOM+2.24%ASMLa-1.54%JNJ-0.76%INTC+1.69%MA-0.59%0700.HK-1.94%ORCL-0.50%1398.HK+0.79%BAC+0.45%ABBV+0.88%CSCO+0.24%CVX+1.91%COST-0.83%LRCX-1.43%KO-0.92%CAT-0.84%AMAT-0.83%AP2d-0.65%0005.HK-0.78%HSBA.L-1.45%UNH-1.94%DELL+0.29%MS-0.42%PG-2.02%GE-2.83%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX-0.96%HD-1.04%GS-0.75%0939.HK+1.66%NZDJPY-2.22%CHFJPY-1.73%USDJPY-1.64%AUDJPY-1.55%EURJPY-1.46%CADJPY-1.44%GBPJPY-1.39%GBPNZD+0.83%NZDCAD-0.80%EURNZD+0.79%AUDNZD+0.70%NZDUSD-0.60%NZDCHF-0.52%GBPTRY+0.41%GBPCHF+0.33%GBPHKD+0.32%GBPMXN-0.28%CADCHF+0.28%EURCHF+0.27%GBPUSD+0.25%GBPZAR+0.22%EURZAR+0.22%EURNOK+0.21%USDZAR+0.21%USDNOK+0.20%NZDSGD+0.19%USDCAD-0.19%AUDCHF+0.19%EURUSD+0.18%NZDMXN+0.17%USDILS+0.16%CHFNOK+0.16%AUDCAD-0.14%GBPAUD+0.14%AUDDKK-0.12%USDTHB+0.12%NOKJPY-0.11%USDTRY+0.11%USDCHF+0.10%EURCZK-0.09%EURAUD+0.09%AUDNOK+0.09%AUDUSD+0.09%EURSEK+0.08%GBPSGD+0.07%EURSGD+0.07%EURPLN+0.07%USDSEK+0.07%USDSGD+0.06%USDPLN+0.06%USDMXN+0.06%AUDSGD-0.05%EURGBP-0.05%USDCOP-0.04%PLNJPY+0.03%USDCNH-0.03%SGDJPY+0.03%GBPCAD+0.03%CHFSEK+0.02%EURCAD-0.02%CHFSGD+0.02%USDHKD+0.01%USDDKK-0.01%EURDKK0.00%EURCNH0.00%EURHKD0.00%COFFEE-2.46%SUGAR+1.85%XPTUSD-1.72%COTTON+1.40%COCOA-1.30%GAGUSD-1.06%XAGUSD-1.04%HG1-0.97%USOIL+0.67%S1+0.53%C1+0.47%UKOIL+0.47%BTCUSD-0.43%ETHUSD0.00%USDTUSD-0.03%XRPUSD-1.28%SOLUSD-0.49%TRXUSDT+0.42%ZECUSDT-1.76%DOGEUSD-1.44%XMRUSDT-0.83%LINKUSD-0.08%XLMUSD-1.08%BCHUSDT-1.93%LTCUSD-1.59%UNIUSD-2.13%TONUSD+24.88%HBARUSDT-1.31%SUIUSD-1.38%TAOUSDT-1.11%AAVEUSD-1.67%DOTUSDT-2.18%ICPUSDT-1.08%ONDOUSDT-2.09%WLDUSDT-1.95%ATOMUSDT-2.11%ARBUSDT-0.27%JUPUSDT-2.96%INJUSDT-2.70%STXUSDT-2.70%FETUSDT-2.39%TIAUSDT-0.87%SEIUSDT-3.91%PYTHUSDT-1.24%IMXUSDT-2.27%WIFUSDT-2.93%GRTUSDT-2.33%OPUSDT-1.99%POLUSDT-3.22%IOTAUSDT-2.53%AXSUSDT-2.04%FARTCOINUSDT-1.57%EOSUSDT+0.06%DYDXUSDT-0.80%ORDIUSDT+0.59%GALAUSDT-3.09%NOTUSDT-0.68%RONINUSDT-0.71%
MR

Monte Rosa Therapeutics, Inc. (GLUE)

NASDAQ • Healthcare

$14.26
-$0 (-0.1%)
Market closed

Last close at September 9, 2026 at 20:00 UTC

Open$14.28
Day Range$14.13 - $14.87
Avg. Volume (3M)1M
Market Cap$1.2B
52 Week Range
$4.8$25.77
Next EarningsIn 56 daysNov 5, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$8.9M100%
Gross Profitminus cost of goods$8.9M100%

Fundamentals & Financials

Revenue (TTM)
$28.7M
Net Income (TTM)
-$161.1M
EPS (TTM)
-$2.18
ROA (TTM)
-23.15%
Current Ratio
9.52

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

-53.6%Q1 2026-$0.54
-60.7%Q2 2026-$0.45
-13.0%Q3 2026-$0.43
Next

Nov 5

in 56 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Miss -13.0%

Monte Rosa Therapeutics trailed consensus on both the top and bottom line in the second fiscal quarter of 2026, reported August 6, 2026, with revenue down 61.3% to about $9.0 million and adjusted EPS of -$0.43 versus the -$0.38 estimate (difference -$0.05, verdict: trailed). Revenue of $9.0 million also trailed the $12.9 million estimate (-31%, verdict: trailed) and was down from $23.2 million a year ago. With gross profit matching revenue at about $9.0 million, the quarter’s losses were driven below the gross line, as operating income came in at roughly -$49.1 million. Net income was -$43.4 million, down from -$12.3 million a year ago, while adjusted EPS declined from -$0.15 a year ago alongside the wider net loss. For the next period, consensus calls for EPS of -$0.36 on revenue of $18.9 million.

View full earnings history

About Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics, Inc. develops precision medicines that harness the body's own protein-disposal machinery to eliminate therapeutically relevant targets as a NASDAQ-listed biotechnology company. In FY2025, it generated $123.7 million in revenue. The company was founded in 2019 and is based in Boston, Massachusetts.

Name
Monte Rosa Therapeutics, Inc.
CEO
Markus Warmuth
Website
www.monterosatx.com
Industry
Healthcare
Year Founded
2019
Employees
173

Today's Snapshot

AI-generated

GLUE closed slightly lower at 14.26, in line with a flat sector. Monte Rosa Therapeutics started a Phase 2 clinical trial for an experimental treatment.

Trading Volume

Above 10d avg 1.0M

1M

vs S&P 500 Today

Moderate Outperformance

+0.35%

Updated: September 9, 2026 at 20:13 UTC

Technical Indicators

0 Buy3 Neutral5 Sell
GLUE exhibits clear technical weakness with a cluster of bearish signals. Short- and medium-term averages sit well above the current price and long-term averages also point lower, while a high ADX indicates a strong downtrend. Volume measures show distribution and momentum indicators are negative, and average true range is elevated relative to price, underscoring heightened downside volatility. Bollinger bands are wide enough to reflect the move but the price remains near the lower band. Technical takeaway: Strong Sell.
All signals
  • EMA (5 indicators)$14.28 - $17.73
    Sell
  • RSI (14)39.33
    Neutral
  • Stochastic %K (14, 3, 3)33.91
    Neutral
  • MACD Level (12, 26)-1.09
    Neutral

Peers & Related Assets

VIRVir Biotechnology, Inc.
$10.81-3.3%
AVBPArriVent BioPharma, Inc.
$29.79-1.6%
MGTXMeiraGTx Holdings plc
$13.26-2.0%
REPLReplimune Group, Inc.
$14.45-2.2%
GERNGeron Corporation
$1.4-7.3%
TBPHTheravance Biopharma Inc
$17.060.0%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.